PMID- 30863364
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200225
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 10
DP  - 2019
TI  - Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in 
      Future Osteoporosis Treatment.
PG  - 75
LID - 10.3389/fendo.2019.00075 [doi]
LID - 75
AB  - Bone homeostasis displays a circadian rhythm with increased resorption during the 
      night time as compared to day time, a difference that seems-at least partly-to be 
      caused by food intake during the day. Thus, ingestion of a meal results in a 
      decrease in bone resorption, but people suffering from short bowel syndrome lack 
      this response. Gut hormones, released in response to a meal, contribute to this 
      link between the gut and bone metabolism. The responsible hormones appear to 
      include glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like 
      peptide-1 (GLP-1), known as incretin hormones due to their role in regulating 
      glucose homeostasis by enhancing insulin release in response to food intake. They 
      interact with their cognate receptors (GIPR and GLP-1R), which are both members 
      of the class B G protein-coupled receptors (GPCRs), and already recognized as 
      targets for treatment of metabolic diseases, such as type 2 diabetes mellitus 
      (T2DM) and obesity. Glucagon-like peptide-2 (GLP-2), secreted concomitantly with 
      GLP-1, acting via another class B receptor (GLP-2R), is also part of this 
      gut-bone axis. Several studies, including human studies, have indicated that 
      these three hormones inhibit bone resorption and, moreover, that GIP increases 
      bone formation. Another hormone, peptide YY (PYY), is also secreted from the 
      enteroendocrine L-cells (together with GLP-1 and GLP-2), and acts mainly via 
      interaction with the class A GPCR NPY-R2. PYY is best known for its effect on 
      appetite regulation, but recent studies have also shown an effect of PYY on bone 
      metabolism. The aim of this review is to summarize the current knowledge of the 
      actions of GIP, GLP-1, GLP-2, and PYY on bone metabolism, and to discuss future 
      therapies targeting these receptors for the treatment of osteoporosis.
FAU - Schiellerup, Sine Paasch
AU  - Schiellerup SP
AD  - Laboratory of Molecular Pharmacology, Department of Biomedical Sciences, Faculty 
      of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Skov-Jeppesen, Kirsa
AU  - Skov-Jeppesen K
AD  - Department of Biomedical Sciences, Faculty of Health and Medical Sciences, 
      University of Copenhagen, Copenhagen, Denmark.
AD  - Faculty of Health and Medical Sciences, Novo Nordisk Foundation (NNF) Center for 
      Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
FAU - Windelov, Johanne Agerlin
AU  - Windelov JA
AD  - Department of Biomedical Sciences, Faculty of Health and Medical Sciences, 
      University of Copenhagen, Copenhagen, Denmark.
AD  - Faculty of Health and Medical Sciences, Novo Nordisk Foundation (NNF) Center for 
      Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
FAU - Svane, Maria Saur
AU  - Svane MS
AD  - Department of Biomedical Sciences, Faculty of Health and Medical Sciences, 
      University of Copenhagen, Copenhagen, Denmark.
FAU - Holst, Jens Juul
AU  - Holst JJ
AD  - Department of Biomedical Sciences, Faculty of Health and Medical Sciences, 
      University of Copenhagen, Copenhagen, Denmark.
AD  - Faculty of Health and Medical Sciences, Novo Nordisk Foundation (NNF) Center for 
      Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
FAU - Hartmann, Bolette
AU  - Hartmann B
AD  - Department of Biomedical Sciences, Faculty of Health and Medical Sciences, 
      University of Copenhagen, Copenhagen, Denmark.
AD  - Faculty of Health and Medical Sciences, Novo Nordisk Foundation (NNF) Center for 
      Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
FAU - Rosenkilde, Mette Marie
AU  - Rosenkilde MM
AD  - Laboratory of Molecular Pharmacology, Department of Biomedical Sciences, Faculty 
      of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190226
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
PMC - PMC6399108
OTO - NOTNLM
OT  - GIP
OT  - GLP-1
OT  - GLP-2
OT  - PYY
OT  - bone metabolism
OT  - gut hormones
OT  - osteoporosis
EDAT- 2019/03/14 06:00
MHDA- 2019/03/14 06:01
PMCR- 2019/01/01
CRDT- 2019/03/14 06:00
PHST- 2018/09/20 00:00 [received]
PHST- 2019/01/28 00:00 [accepted]
PHST- 2019/03/14 06:00 [entrez]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/03/14 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2019.00075 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2019 Feb 26;10:75. doi: 10.3389/fendo.2019.00075. 
      eCollection 2019.